

No: 09/2025/CV-MP

Hanoi, January 24, 2025

**INFORMATION DISCLOSURE**

To: - State Securities Commission;  
- Hanoi Stock Exchange

1. Company Name: **MEDIPLANTEX NATIONAL PHARMACEUTICAL  
JOINT STOCK COMPANY**

Stock Code: MED

Address: No. 358, Giai Phong Road, Hoang Liet Ward, Thanh Xuan District, Ha  
Noi City.

Phone: 024.3864 3363

Fax: 024.3864 1584

Email: info@mediplantex.com

**Type of information disclosure:** ☒ Periodic ☐ Extraordinary ☐ As required

2. Information Disclosure Content:

Report on Corporate Governance in 2024

3. This information was published on the company's website on January 24, 2025  
at the link: <http://www.mediplantex.com/vi/thong-tin-co-dong.html>.

We hereby commit that the information published above is accurate and are fully  
legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL  
JOINT STOCK COMPANY**

**GENERAL DIRECTOR**



*Mai Nhật Thanh*

**MEDIPLANTEX NATIONAL  
PHARMACEUTICAL  
JOINT STOCK COMPANY**

**THE SOCIALIST REPUBLIC OF VIETNAM**  
**Independence – Freedom – Happiness**

*Ha Noi, January 24, 2025*

## **REPORT ON CORPORATE GOVERNANCE 2024**

To:               - State Securities Commission;  
                      - Hanoi Stock Exchange.

- Company Name: **Mediplantex National Pharmaceutical Joint Stock Company.**
- Address: No. 358, Giai Phong Road, Hoang Liet Ward, Thanh Xuan District, Ha Noi City.
- Phone: 024.38641552                      Email: [info@mediplantex.com](mailto:info@mediplantex.com)
- Charter Capital: 124,100,000,000 VND.
- Stock Code: MED.
- Governance Model: General Meeting of Shareholders, Board of Directors, Board of Supervisors, and General Director.
- Implementation of Internal Audit: Not implemented.

### **I. Activities of the General Meeting of Shareholders**

Information on resolutions of the General Meeting of Shareholders:

No.	Resolution No.	Date of issue	Contents
1	01/2024/NQ-DHDCD	June 26, 2024	<ol style="list-style-type: none"><li>1. Report of the Board of Directors on the Results of the Board's Activities in 2023, the 2020–2024 term, and the Orientation for the Implementation of the Production and Business Plan for 2024, the 2024–2029 term;</li><li>2. Report of the Board of Management on the Results of Production and Business Activities in 2023 and the Orientation for the Implementation of the Production and Business Plan for 2024;</li><li>3. Report of the Board of Supervisors on the Results of Activities for the 2020–2024 term and the Orientation for Activities in the 2024–2029 term;</li><li>4. Proposal for Approval of the Conclusion of the 2020–2025 Term of the Board of Directors and the Election of Board Members for the 2024–2029 Term;</li><li>5. Proposal for Approval of the Conclusion of the 2020–2025 Term of the Board of Supervisors</li></ol>



			<p>and the Election of Board of Supervisors Members for the 2024–2029 Term;</p> <p>6. Proposal for Approval of the Audited Financial Statements for 2023;</p> <p>7. Proposal for Selecting an Independent Auditing Firm for the Financial Statements of 2024;</p> <p>8. Proposal for Approval of the Profit Distribution Plan, Dividend Payout Ratio for 2023, and the Proposed Profit Distribution Plan, Dividend Payout Ratio for 2024;</p> <p>9. Proposal for Approval of the Remuneration for the Board of Directors and the Board of Supervisors in 2024;</p> <p>10. Proposal for Approval of Adjustments to the Plan for Mobilizing and Utilizing Capital for Investment in the "Pharmaceutical Science and Technology Center and GMP EU-Compliant Pharmaceutical Manufacturing Facility";</p> <p>11. Proposal for Approval of Amendments and Supplements to the Charter and Internal Regulations on Corporate Governance.</p>
--	--	--	--

## II. Board of Directors in 2024

### 1. Information about the members of the Board of Directors

No.	Members of the Board of Directors	Position	Date becoming/ceasing to be the member of the Board of Directors	
			Date of appointment	Date of dismissal
1	Tran Hoang Dung	Chairman of the board	June 26, 2024	
2	Tran Xuan Dinh	Board member	June 26, 2024	
3	Tran Nguyen Hoang An	Board member	June 26, 2024	
4	Nguyen Thi Thuy	Board member	June 26, 2024	
5	Thai Khac Minh	Independent board member	June 26, 2024	
6	Doan Thi Hong Thuy	Chairman of the board		June 26, 2024
7	Tran Hoang Dung	Deputy Chairman of the board		June 26, 2024
8	Le Hong Trung	Board member		June 26, 2024
9	Nguyen Ngoc Tuyen	Board member		June 26, 2024
10	Nguyen Tien Phong	Board member		June 26, 2024
11	Nguyen Van Khai	Board member		June 26, 2024

12	Do Van Tan	Independent board member		June 26, 2024
----	------------	--------------------------	--	---------------

## 2. Meetings of the Board of Directors

No.	Members of the Board of Directors	Number of Meetings Attended	Attendance Rate	Reasons for Absence
1	Doan Thi Hong Thuy	5/12	42%	Dismissed from June 26, 2024
2	Tran Hoang Dung	12/12	100%	
3	Le Hong Trung	5/12	42%	Dismissed from June 26, 2024
4	Nguyen Ngoc Tuyen	5/12	42%	Dismissed from June 26, 2024
5	Nguyen Tien Phong	5/12	42%	Dismissed from June 26, 2024
6	Do Van Tan	5/12	42%	Dismissed from June 26, 2024
7	Nguyen Van Khai	5/12	42%	Dismissed from June 26, 2024
8	Tran Xuan Dinh	7/12	58%	Appointed from June 26,2024
9	Tran Nguyen Hoang An	7/12	58%	Appointed from June 26,2024
10	Nguyen Thi Thuy	7/12	58%	Appointed from June 26,2024
11	Thai Khac Minh	7/12	58%	Appointed from June 26,2024

## 3. Supervision of the Board of Directors over the Board of Management

- In 2024, despite facing numerous challenges in its business operations, the company maintained financial stability, and information related to its production and business activities was always disclosed transparently and promptly.

- The Board of Directors enhanced corporate governance efforts, supervised, and controlled various company activities to minimize risks in production and business operations. All of the company's production and business activities were monitored and supervised by the Board of Directors, the Board of Supervisors, and specialized departments to ensure maximum risk mitigation for the company.

- The Board of Directors reviewed compliance with and adherence to resolutions of the General Meeting of Shareholders, resolutions of the Board of Directors, the provisions of the Law on Enterprise 2020, the Law on Securities, relevant legal documents, as well as the company's Charter of Organization and Operation, Corporate Governance Regulations, and Financial Management Regulations.

## 4. Activities of the Committees under the Board of Directors: None.

## 5. Resolutions/Decisions of the Board of Directors

No.	Resolution/Decision No.	Content	Approval Rate
1	<b>01/2024/NQ-HDQT</b> dated January 15, 2024	Approved the proposal of the General Director regarding the recruitment for the position of Deputy General Director in charge of Finance & Accounting.	100%



No.	Resolution/Decision No.	Content	Approval Rate
2	<b>02/2024/NQ-HDQT</b> dated 06/03/2024	Approved the plan for Mediplantex National Pharmaceutical Joint Stock Company to borrow capital from BIDV (Bank for Investment and Development of Vietnam) (directly managing client unit: Hong Ha Branch)	100%
3	<b>03/2024/NQ-HDQT</b> dated 17/04/2024	Approved the content of temporarily postponing the organization of the 2024 Annual General Meeting of Shareholders (AGM).	100%
4	<b>04/2024/NQ-HDQT</b> dated 07/05/2024	<p>1. Agreement on the time of the 2024 AGM:</p> <ul style="list-style-type: none"> <li>- Time: The meeting will commence at 8:30 AM, Wednesday, June 26, 2024.</li> <li>- Venue: In Hanoi (survey for a suitable location to host the meeting).</li> <li>- Record date for shareholder list: May 27, 2024.</li> </ul> <p>2. Agreement on the content of the meeting:</p> <ul style="list-style-type: none"> <li>- Report by the Board of Directors (BOD) on the performance of the BOD in 2023 and the direction for implementing the BOD's activity plan in 2024.</li> <li>- Report by the Board of Management on business performance in 2023 and the direction for implementing the business plan in 2024.</li> <li>- Report by the Board of Supervisors on performance and supervision in 2023 and the direction for activities in 2024.</li> <li>- Report on the progress of the Science and Technology Pharmaceutical Center project and the factory for applying pharmaceutical production meeting GMP EU standards.</li> <li>- Approval of the audited financial statements for 2023.</li> <li>- Selection of an independent auditing firm for the 2024 financial statements.</li> <li>- Approval of the profit distribution plan and dividend payout ratio for 2023 and the proposed profit distribution plan and dividend payout ratio for 2024.</li> <li>- Approval of remuneration for the BOD and the Board of Supervisors for 2024.</li> </ul>	100%

No.	Resolution/Decision No.	Content	Approval Rate
		<ul style="list-style-type: none"> <li>- Approval of the dismissal of a member of the BOD and the election of a replacement member.</li> <li>- Other matters under the authority of the meeting.</li> </ul>	
5	<b>05/2024/NQ-HDQT</b> dated June 12,2024	<p>1. Agreed to approve the report on the implementation of the business plan for the first five months of 2024.</p> <p>2. Agreed to approve the following reports and submissions:</p> <ul style="list-style-type: none"> <li>- Report by the Board of Management on business performance in 2023 and the direction for implementing the 2024 business plan.</li> <li>- Submission for approval of the audited financial statements for 2023.</li> <li>- Submission for the selection of an independent auditing firm for the 2024 financial statements.</li> <li>- Submission for approval of remuneration for the Board of Directors (BOD) and the Board of Supervisors (BOS) for 2024.</li> </ul> <p>3. Agreed to supplement the contents of Submission No. 03/2024/TTr-DHĐCĐ as follows:</p> <ul style="list-style-type: none"> <li>- Bonus allocation for the Board of Management: 1% of profit upon achieving the profit target. An additional bonus of 5% of the value of profits exceeding the target.</li> <li>- Bonus allocation for the BOD and BOS: 1% of profit upon achieving the profit target. An additional bonus of 5% of the value of profits exceeding the target.</li> <li>- Dividend payout ratio for 2023: 9% of charter capital.</li> <li>- For 2024, plan to allocate 1% for the Board of Management and 1% for the BOD and BOS.</li> <li>- In the event that 2024's post-tax profit exceeds the target approved by the General Meeting of Shareholders (GMS):</li> </ul>	100%



No.	Resolution/Decision No.	Content	Approval Rate
		<p>An additional bonus for the Board of Management at the rate of 5% of the post-tax profit exceeding the target.</p> <p>An additional bonus for the BOD and BOS at the rate of 10% of the post-tax profit exceeding the target.</p> <p>4. Assigned the General Director to supplement explanations and reasons for the increase in project investment capital and adjust the capital mobilization plan in Submission No. 05/2024/TTr-ĐHĐCĐ: Approval of adjustments to the capital mobilization plan and an increase in total investment capital for the project "Pharmaceutical Science and Technology Center and Pharmaceutical Production Facility Meeting GMP-EU Standards."</p> <p>5. Agreed to approve the early conclusion of the 2020-2025 term for the BOD and BOS.</p> <p>6. Added two submissions to the documents for the 2024 General Meeting of Shareholders:</p> <ul style="list-style-type: none"> <li>- Submission for approval of the conclusion of the 2020–2025 term of the BOD and the election of BOD members for the 2024–2029 term.</li> <li>- Submission for approval of the conclusion of the 2020–2025 term of the BOS and the election of BOS members for the 2024–2029 term.</li> </ul>	
6	<b>06/2024/NQ-HDQT</b> dated June 26, 2024	<p>Agreed to approve the following contents:</p> <p>1. Appointment: Mr. Tran Hoang Dung</p> <ul style="list-style-type: none"> <li>- Position: Chairman of the Board of Directors of Mediplantex Central Pharmaceutical Joint Stock Company for the 2024–2029 term.</li> <li>- Term of appointment: From June 26, 2024, until the end of the 2024–2029 term of the Board of Directors.</li> </ul> <p>2. Dismissal: Mr. Tran Hoang Dung from the position of General Director and legal representative of Mediplantex Central Pharmaceutical Joint Stock Company for the 2020–2025 term.</p> <ul style="list-style-type: none"> <li>- Effective date of dismissal: From June 26, 2024.</li> </ul>	100%

No.	Resolution/Decision No.	Content	Approval Rate
		<p>3. Appointment: Mr. Tran Xuan Dinh</p> <ul style="list-style-type: none"> <li>- Position: General Director and legal representative of Mediplantex Central Pharmaceutical Joint Stock Company.</li> <li>- Term of appointment: From June 26, 2024, until the end of the 2024–2029 term of the Board of Directors.</li> </ul>	
7	<b>07/2024/NQ-HDQT</b> dated June 26, 2024	Approved the adjustment of the project: "Center for Pharmaceutical Science and Technology and the Factory for the Application of Pharmaceutical Production Meeting GMP-EU Standards".	100%
8	<b>08/2024/NQ-HDQT</b> dated June 26, 2024	<p><b>Approval of the Following Appointments:</b></p> <p>1. Appointment: Mr. Le Hong Trung Position: Deputy General Director of Business, Mediplantex Central Pharmaceutical Joint Stock Company Term of Appointment: From July 1, 2024, until the end of the 2024-2029 term of the Board of Directors or until further notice.</p> <p>2. Appointment: Mr. Nguyen Tien Phong Position: Deputy General Director of Production, Mediplantex Central Pharmaceutical Joint Stock Company Term of Appointment: From July 1, 2024, until the end of the 2024-2029 term of the Board of Directors or until further notice.</p> <p>3. Appointment: Mr. Tran Nguyen Hoang An Position: Deputy General Director of Planning and International Business, Mediplantex Central Pharmaceutical Joint Stock Company Term of Appointment: From July 1, 2024, until the end of the 2024-2029 term of the Board of Directors or until further notice.</p> <p>4. Appointment: Mr. Tran Anh Tuan Position: Chief Accountant, Mediplantex Central Pharmaceutical Joint Stock Company Term of Appointment: From July 1, 2024, until the end of the 2024-2029 term of the Board of Directors or until further notice.</p>	100%
9	<b>09/2024/NQ-HDQT</b> dated July 18, 2024	<p><b>Approval of the Following Resolutions:</b></p> <p>1. Approval of the production and business performance report for the first six months of 2024 and the production and business plan for the remaining six months of 2024.</p>	100%



No.	Resolution/Decision No.	Content	Approval Rate
		<p>2. Approval of the bonus allocation for meeting the 2023 production and business goals for the Board of Management, Board of Directors, and Board of Supervisors for the 2020-2024 term.</p> <p>3. Approval of the monthly remuneration for the Board of Directors and the Board of Supervisors for 2024.</p> <p>4. Approval of the timeline for the distribution of dividends for 2023:</p> <ul style="list-style-type: none"> <li>- Final registration date: July 31, 2024</li> <li>- Dividend payment date: August 20, 2024</li> <li>- Dividend for 2023 to be paid in cash at a rate of 9% of charter capital.</li> </ul> <p>5. Approval of Proposal No. 07/2024/TTr-HĐQT by the General Director regarding the liquidation of old cars and the procurement of new vehicles.</p> <p>6. Approval of Proposal No. 08/2024/TTr-HĐQT by the General Director regarding the repair and renovation of Factory 1 GMP Traditional Medicine.</p> <p>7. Approval of the investment cooperation strategy, including identifying potential investors aligned with the company's development direction.</p> <p>8. Approval of the establishment of the Legal Department.</p>	
10	<b>10/2024/NQ-HĐQT</b> dated August 27, 2024	Approval of the loan by Mediplantex Central Pharmaceutical Joint Stock Company from Vietcombank – Head Office Branch to support production and business activities, with a total credit limit at Vietcombank – Head Office Branch of VND 70,000,000,000 (In words: Seventy billion Vietnamese dong).	100%
11	<b>11/2024/NQ-HĐQT</b> dated September 04, 2024	Approval of the dismissal of Mr. Le Hong Trung from the position of Deputy General Director of Business effective from September 1, 2024.	100%
12	<b>12/2024/NQ-HĐQT</b> dated October 11, 2024	<p><b>Approval of the Following Resolutions:</b></p> <p>1. Report on production and business performance for the first nine months of 2024 and the production and business plan for the final three months of 2024.</p>	100%

No.	Resolution/Decision No.	Content	Approval Rate
		<ol style="list-style-type: none"> <li>2. Policy on appointing an assistant to the Chairman of the Board of Directors and concurrently assigning the role of Corporate Governance Officer.</li> <li>3. Proposal No. 12/2024/TTr-HĐQT on the dismissal of the Deputy General Director of Production – Mr. Nguyen Tien Phong, effective from November 1, 2024.</li> <li>4. Proposal No. 13/2024/TTr-HĐQT on the appointment of the Deputy General Director of Production – Mr. Le Thanh Lam, effective from November 1, 2024.</li> <li>5. Policy on restructuring the company and implementing enterprise management software.</li> <li>6. Policy on assigning the General Director to review the My Dinh project and negotiate with the partner to terminate and liquidate the contract.</li> </ol>	
13	<b>13/2024/NQ-HĐQT</b> dated November 01, 2024	<p>Approval of contracts and transactions between Mediplantex Central Pharmaceutical Joint Stock Company and related parties of the Company as follows:</p> <ol style="list-style-type: none"> <li>1. Contracting party: AN HY Pharmaceutical One Member Limited Liability Company – a related party to the Company insider: Chairman of the Board of Directors, Mr. Tran Hoang Dung.</li> <li>2. Transaction details: <ul style="list-style-type: none"> <li>- <b>Type of contract:</b> Pharmaceutical sales contract</li> <li>- <b>Estimated transaction value:</b> VND 35,000,000,000</li> <li>- <b>Execution period:</b> Year 2025</li> </ul> </li> </ol>	100%
14	<b>14/2024/NQ-HĐQT</b> dated December 13, 2024	<p>Approved the following contents:</p> <ol style="list-style-type: none"> <li>1. Report on the production and business performance for 11 months and the expected production and business results for 2024.</li> <li>2. Proposal No. 10/2024/TTr-BOD on issuing internal management regulations of the company.</li> <li>3. Proposal No. 15/2024/TTr-BOD on extending the loan at Military Commercial Joint Stock Bank – Dien Bien Phu Branch.</li> </ol>	100%



No.	Resolution/Decision No.	Content	Approval Rate
		<p>4. Policy to hire a legal consulting firm to definitively resolve the outstanding issues related to the My Dinh project.</p> <p>5. Policy to replace the General Director to ensure compliance with the Law on Enterprises and the company's charter. Assign the Chairman of the Board of Directors to search for and propose candidates for the position of General Director.</p>	

### III. Board of Supervisors

#### 1. Information about the members of the Board of Supervisors

No.	Members of the Board of Supervisors	Position	Date of Appointment	Date of Dismissal	Professional Qualification
1	Ho Ngoc Tuan	Head	June 26, 2024		Bachelor of Engineering in Construction
2	Ha Thi Bich Hanh	Member	June 26, 2024		Bachelor of Pharmacy
3	Do Ngoc Thuy	Member	June 26, 2024		Bachelor of Accounting
4	Phung Minh Thom	Head		June 26, 2024	Bachelor of Accounting
5	Duong Thi Minh Nguyet	Member		June 26, 2024	Bachelor of Accounting
6	Tran Ngoc Ha	Member		June 26, 2024	Bachelor of Accounting

#### 2. Meetings of the Board of Supervisors

No.	Members of the Board of Supervisors	Number of Meetings Attended	Attendance Rate	Voting Percentage	Reasons for Absence
1	Phung Minh Thom	2/5	40%	100%	Dismissed from June 26, 2024
2	Duong Thi Minh Nguyet	2/5	40%	100%	
3	Tran Ngoc Ha	2/5	40%	100%	
4	Ho Ngoc Tuan	3/5	60%	100%	Appointed from June 26, 2024
5	Ha Thi Bich Hanh	3/5	60%	100%	
6	Do Ngoc Thuy	3/5	60%	100%	

#### 3. Supervisory Activities of the Board of Supervisors over the Board of Directors and the General Director

The Board of Supervisors represents shareholders in overseeing all production, business, management, and operational activities of the company. The Board of Supervisors serves a 5-year term and consists of three members. The Board of Supervisors holds regular meetings in accordance with its operating regulations. In 2024, the Head of the Board of Supervisors was invited to attend all periodic meetings of the Board of Directors to stay informed about the

company's management policies and strategies. The Board of Supervisors is responsible for monitoring and inspecting the legality and rationality of the company's management and business operations, as well as the accuracy of accounting records and financial statements. It is tasked with recommending corrective measures for any detected violations. The Board regularly provides written reports to the Board of Directors on its activities and reports to the General Meeting of Shareholders on the accuracy, truthfulness, and legality of the company's management and business operations.

**4. Coordination Activities between the Board of Supervisors, the Board of Directors, the Board of Management, and other Management Personnel**

In 2024, the Board of Supervisors received close cooperation and favorable conditions from the Board of Directors, the Board of Management, and other managers to effectively carry out its supervisory duties. This was facilitated through the provision of complete documents and information related to the company's governance, production and business activities, and financial matters.

**5. Other activities of the Board of Supervisors: None**

**IV. Board of Management**

No.	Members of the Board of Management	Date of Birth	Qualification	Date of Appointment
1	Tran Xuan Dinh		Bachelor	June 26, 2024
2	Tran Nguyen Hoang An		Bachelor	July 01, 2024
3	Le Thanh Lam		Bachelor of Pharmacy	November 01, 2024

**V. Chief Accountant**

Name	Date of Birth	Qualification	Date of Appointment
Tran Anh Tuan		Bachelor of Finance – Accounting	July 01, 2024

**VI. Corporate Governance Training: None.**

**VII. Lists of the Company's Affiliated Persons and their Transactions with the Company**

**1. List of affiliated persons of the company:**



Name of organization/individual	Position (for insider)	ID No.	Date of issue	Place of issue	Address	Time of starting to be affiliated person	Time of ending to be affiliated person	Relationship with the Company
Ms. Doan Thi Hong Thuy	Chairman of the BOD (dismissed)						June 26, 2024	
Mr. Tran Hoang Dung	Chairman of the BOD					June 26, 2024		
Mr. Le Hong Trung	Member of the BOD (dismissed)						June 26, 2024	
Mr. Nguyen Tien Phong	Member of the BOD (dismissed)						June 26, 2024	
Mr. Nguyen Ngoc Tuyen	Member of the BOD (dismissed)						June 26, 2024	
Mr. Nguyen Van Khai	Member of the BOD (dismissed)						June 26, 2024	
Mr. Do Van Tan	Member of the BOD (dismissed)						June 26, 2024	
Mr. Phung Minh Thom	Head of the BOS (dismissed)						June 26, 2024	

Ms. Duong Thi Minh Nguyet	Member of the BOS (dimissed)							June 26, 2024	
Mr. Tran Ngoc Ha	Member of the BOS (dimissed)							June 26, 2024	
Mr. Nguyen Chi Kien	Deputy General Manager (dimissed)							June 26, 2024	
Mr. Le Hong Trung	Deputy General Manager (dimissed)							September 01,2024	
Mr. Nguyen Tien Phong	Deputy General Manager (dimissed)							November 1, 2024	
Ms. La Thi Trang Nhung	Chief Accountant (dimissed)							June 26, 2024	
Mr. Tran Xuan Dinh	Member of BOD, General Director							June 26, 2024	
Mr. Tran Nguyen Hoang An	Member of the BOD - Deputy General Director							June 26, 2024	



Mrs. Nguyen Thi Thuy	Member of the BOD					June 26, 2024		
Mr. Thai Khac Minh	Member of the BOD					June 26, 2024		
Mr. Tran Anh Tuan	Chief Accountant					July 01, /2024		
Mr. Le Thanh Lam	Deputy General Manager					November 1, 2024		
Mr. Ho Ngoc Tuan	Head of the BOS					June 26, 2024		
Ms. Ha Thi Bich Hanh	Member of the BOS					June 26, 2024		
Ms. Do Ngoc Thuy	Member of the BOS					June 26, 2024		
Mrs. Chu Huyen Trang	Company Secretary					January 03, 2023		
<b>List of major shareholders</b>								
Ms. Nguyen Ngoc Xuan Trang								

Mr. Tran Hoang Dung	Chairman of the BOD								
Mrs. Tran Nguyen Hoang Phuc									
Vietnam Pharmaceutical Corporation									
Capital Ownership Representative									
Mr. Nguyen Van Khai	Member of the BOD							June 26, 2024	
Mrs. Nguyen Thi Thuy	Member of the BOD							June 26, 2024	
Authorized person to disclose information									
Mr. Tran Xuan Dinh	Member of the BOD - General Director							June 26, 2024	

(\*) Note: The list of affiliated persons of insiders, as listed in Section VIII.1 of this Report, is therefore not detailed here

2. Transactions between the company with its affiliated persons or between the company and its major shareholders, internal persons, or their affiliated persons:

No.	Name of organization/ individuals	Relationship with the company	Certificate Number *, date of issue, place of issue	Head office address/	Time of transaction with the company	Resolution No. Decision of the General Meeting of Shareholders/ Board of Directors passed	Contents , quantity, total transaction value	Note
-----	-----------------------------------	-------------------------------	---	----------------------	--------------------------------------	---	--	------



1	An Hy Pharmaceutical Company Limited	Affiliated person of Mr Tran Hoang Dung – Chairman of the BOD	Business Registration Certificate No.: 0309738339 issued on May 22, 2017 by the Department of Planning and Investment of Ho Chi Minh City	No. 506/15/34 3/2 Street, Ward 14, District 10, HCM	In 2024		Goods trading transactions. Total transaction value: 22,475,139,763 VND	
---	--------------------------------------	---	---	---	---------	--	---	--

**3. Transactions between the listed company's internal persons or their affiliated persons with the company's subsidiaries or companies that the listed company exercises controlling power:** None.

**4. Transactions between the Company and other Entities:**

4.1. Transactions between the company with the companies where members of the BOD, members of the Board of Supervisors, General Director, and other management personnel have been or are currently founders, members of the BOD, or General Director within the past three (03) years (as of the reporting date):

No.	Name of organization/ individuals	Relationship with the company	Certificate Number *, date of issue, place of issue	Head office address/	Time of transaction with the company	Resolution No. Resolution/ Decision of the General Meeting of Shareholders/ Board of Directors passed	Contents , quantity, total transaction value	Note
1	Northern Medibros Medicine „JSC	Mr Le Hong Trung, Mr. Nguyen Tien Phong (dismissed) are members of the BOD	Business Registration Certificate No.: 0107575836 issued on September 25, 2016 by	No. 358 Giai Phong, Phuong Liet Ward, Thanh Xuan District, Hanoi	In 2024		Goods trading transactions. Total transaction value: 65,204,587,157 VND	

			Department of Planning and Investment of Hanoi						
2	<b>Medibros Central Pharmaceutical ,JSC</b>	Mr. Nguyen Tien Phong (dismissed) are members of the BOD	Business Registration Certificate No.: 0401696994 issued on September 18, 2015 Department of Planning and Investment of Da Nang City	No. 512, 29/3 Street, Hoa Xuan Ward, Cam Le District, Da Nang City	In 2024			Goods trading transactions. Total transaction value: 10,035,587,888 VND	

**4.2.** Transactions between the company and companies where affiliated persons of members of the BOD, members of the Board of Supervisors, General Director, and other management personnel serve as members of the BOD or General Director: **None.**

**4.3.** Other transactions of the company (if any) that may bring material or non-material benefits to members of the BOD, members of the Board of Supervisors, General Director, and other management personnel: **None.**

### VIII. Share Transactions of Internal Persons and their Affiliated Persons

#### 1. List of internal persons and their affiliated persons:

No.	Full name	Securities trading account	Position at the company	ID card No	Date of issue	Place of issue	Address	Number of shares owned at the end of the period	Percentage of share ownership at the end of the period	Note
1	<b>Mr. Tran Hoang Dung</b>		<b>Chairman of the BOD</b>					<b>1,000,000</b>	<b>8.06 %</b>	
1.1	Tran Hoang Thuong									















